Search Share Prices
Futura Medical's successful erectile dysfunction trials boost share price
(WebFG News) - Futura Medical announced on Wednesday that a pharmacokinetic study of MED2002, the company's gel-based erectile dysfunction (ED) treatment, has yielded positive results.
The study, which commenced in November, evaluated the doses of 0.2%, 0.4%, 0.6% and 0.8% of the gel's active ingredient glyceryl trinitrate (GTN) to assess the viability of different dosages for the treatment of ED.
Higher dosages were found to have caused higher concentrations of the ingredient in the bloodstream, supporting the theory that higher dosages will improve product efficacy.
High doses of the ingredient were "well tolerated" by the subjects of the study, with only mild incidences such as headaches, shown to occur in less than 2% of intercourse attempts, being recorded.
GTN demonstrated a rapid rate of absorption in the study and was directed in the bloodstream just five minutes after the application of the gel.
Futura Medical said this is a key feature of the product as potential competitor products like Viagra and Cialis are taken orally and can take as long as half an hour, an hour or even longer to take effect.
James Barder, chief executive of Futura Medical, said: "We are delighted to report the excellent data from our latest PK study for MED2002. The results show the effectiveness of our DermaSys transdermal technology and demonstrate the potential of MED2002 as a rapid and safe treatment option for erectile dysfunction."
Phase III studies for MED2002 are currently being planned by Futura Medical.
As of 1039 BST, Futura Medical's shares were up 7.69% at 35.00p.